Abstract
To estimate the economic burden of CKD-T2D from a social perspective[1] in two scenarios: the standard of care (SoC) used in Colombia and the standard of care plus Finerenone, a nonsteroidal, selective antagonist of the mineralocorticoid receptor studied for the management of adults with CKD (eGFR ≥ 25mL/min with albuminuria) and T2D.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have